What is the half-life of CJC-1295 (with DAC)?

CJC-1295 (with DAC) has a half-life of Unknown, which is why it's typically administered As needed for optimal therapeutic effect.

How do I reconstitute CJC-1295 (with DAC)?

Add bacteriostatic water to the peptide vial slowly down the side. Typical reconstitution uses 2-3ml of water for a 5mg vial. Gently swirl, do not shake.

What is the half-life of CJC-1295 (with DAC)?

CJC-1295 (with DAC) has a half-life of Unknown, which is why it's typically administered As needed for optimal therapeutic effect.

How do I reconstitute CJC-1295 (with DAC)?

Add bacteriostatic water to the peptide vial slowly down the side. Typical reconstitution uses 2-3ml of water for a 5mg vial. Gently swirl, do not shake.

Healing & Recovery

Phase 2

CJC-1295 (with DAC)

Also known as: CJC-1295 DAC, DAC:GRF

Overview

Key Facts

Primary Goal: Research and therapeutic applications of CJC-1295 (with DAC)

Binds to GHRH receptors on anterior pituitary somatotrophs to stimulate GH release. Drug Affinity Complex binds serum albumin, preventing rapid degradation by DPP-IV.

Dosing Information

Half-Life

to approximately 6-8 days. This allows for sustained GH elevation with less frequent dosing compared to non-DAC variants.Half-Life6-8 days

Typical Dose

1000–2000 mcg

Frequency

1-2 times per week

Cycle Length

8-12 weeks

Administration Routes:

subcutaneous

Benefits

Sustained growth hormone elevation over several days
Increased IGF-1 levels
Enhanced muscle growth and recovery
Improved sleep quality
Reduced body fat over time

Side Effects

Water retention and bloatinguncommonmild

Tingling or numbness in extremitiesuncommonmild

Injection site irritationuncommonmild

Possible cortisol and prolactin increaseuncommonmild

Mechanism of Action

Binds to GHRH receptors on anterior pituitary somatotrophs to stimulate GH release

Drug Affinity Complex binds serum albumin, preventing rapid degradation by DPP-IV

Promotes pulsatile GH secretion over an extended period

Contraindications

Do not use this peptide if any of the following apply:

Active malignancy or history of cancer
Pregnancy or breastfeeding
Diabetic retinopathy

Storage & Reconstitution

Unreconstituted (Powder)

Temperature2–8°C (36–46°F) or -20°C (-4°F) for long-term

DurationUp to 3 months

Reconstituted (Mixed)

Temperature2–8°C (36–46°F)

Duration2-4 weeks

Research Summary

Phase 2

CJC-1295 with DAC has been studied in Phase II clinical trials demonstrating dose-dependent increases in GH and IGF-1 levels sustained over weeks. Research showed 2-10 fold increases in mean GH concentrations after a single injection. Development was paused due to safety concerns in one trial, though the compound remains widely studied in research settings.

Frequently Asked Questions

Common questions about CJC-1295 (with DAC)

UK-Specific Information

Exclusive data points and guidance for UK residents using CJC-1295 (with DAC)

UK Lab Testing

Recommended labs: Medichecks, Thriva (£89-£149 for peptide safety panel)

Generate a trackable link to share this peptide information on TikTok